ProStrakan Group Plc (PSK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details. - Key manufacturing facilities – A list of key manufacturing facilities of the company.
ProStrakan Group plc (ProStrakan) is an international specialty pharmaceutical company. It undertakes the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs. The company’s product portfolio focuses on pain management, cancer treatments and metabolic disorders among others. ProStrakan markets its products in various countries across the world including the UK, the US, Germany, France, Italy, Spain and Sweden. Its development group is located in Galashiels, Scotland and Bedminster, New Jersey, US. ProStrakan developed Sancuso in-house and it has is marketed in the US and Europe. The company is a subsidiary of Kyowa Hakko Kirin Co., Ltd. ProStrakan is headquartered in Galashiels, Scotland.
ProStrakan Group Plc Key Recent Developments
Nov 11, 2013: ProStrakan Announces Board Changes
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy. - Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company. - Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table Of Contents
ProStrakan Group Plc (PSK) - Strategic SWOT Analysis Review Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Section 1 - About the Company 5 ProStrakan Group Plc - Key Facts 5 ProStrakan Group Plc - Key Employees 6 ProStrakan Group Plc - Key Employee Biographies 7 ProStrakan Group Plc - Major Products and Services 8 ProStrakan Group Plc - History 9 ProStrakan Group Plc - Locations And Subsidiaries 13 Head Office 13 Other Locations and Subsidiaries 13 Joint Venture 14 Section 2 - Company Analysis 15 ProStrakan Group Plc - Business Description 15 ProStrakan Group Plc - Corporate Strategy 16 ProStrakan Group Plc - SWOT Analysis 17 SWOT Analysis - Overview 17 ProStrakan Group Plc - Strengths 17 Strength - Synergy Through Kyowa Hakko Kirin 17 Strength - Significant Product Portfolio 17 Strength - Revenue Driven by Growth in Key Products 17 ProStrakan Group Plc - Weaknesses 18 Weakness - Legal Proceedings 18 ProStrakan Group Plc - Opportunities 19 Opportunity - Strategic Alliances 19 Opportunity - Market Potential: Oncology 19 Opportunity - Acquisition of Archimedes Pharma Limited 19 ProStrakan Group Plc - Threats 20 Threat - Intense Competition 20 Threat - Growing Parallel Trade 20 Threat - Uncertain RandD Outcomes 20 ProStrakan Group Plc - Key Competitors 21 Section 3 - Company's Lifesciences Financial Deals and Alliances 22 ProStrakan Group Plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 22 ProStrakan Group Plc, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 23 ProStrakan Group Plc, Recent Deals Summary 24 Section 4 - Appendix 25 Methodology 25 About GlobalData 25 Contact Us 25 Disclaimer 25
List of Tables ProStrakan Group Plc, Key Facts 5 ProStrakan Group Plc, Key Employees 6 ProStrakan Group Plc, Key Employee Biographies 7 ProStrakan Group Plc, Major Products and Services 8 ProStrakan Group Plc, History 9 ProStrakan Group Plc, Other Locations 13 ProStrakan Group Plc, Subsidiaries 13 ProStrakan Group Plc, Joint Venture 14 ProStrakan Group Plc, Key Competitors 21 ProStrakan Group Plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 22 ProStrakan Group Plc, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 23 ProStrakan Group Plc, Recent Deals Summary 24
List of Figures ProStrakan Group Plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 22 ProStrakan Group Plc, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 23